Opens in a new tab or window SAN FRANCISCO -- Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral therapy (ART) avoided rebound for 5 ...
bNAbs have already been investigated as drugs given as infusions ... and are used to contain the active ingredients, the HIV antigens. A vector is much better at getting inside cells than a vaccine ...
Hosted on MSN1mon
Scientists develop new natural killer cell strategy to target HIVMore information: Costin Tomescu et al, Gene-modified NK cells expressing CD64 and preloaded with HIV-specific BNAbs target autologous HIV-1–infected CD4+ T cells by ADCC, The Journal of ...
Broadly neutralising antibodies (bnAbs) have the potential to fill that gap. People living with HIV normally produce HIV-specific antibodies, but these mostly target parts of the virus that are hidden ...
An effective HIV-1 vaccine must therefore elicit antibodies that can neutralize many variants of the virus. While broadly neutralizing antibodies (bnAbs) have been isolated from HIV-1 infected ...
The VRC01-class of potent, broadly neutralizing antibodies (bnAbs) targets the conserved CD4-binding site (CD4bs) of HIV-1 Env which has been a major target of HIV-vaccine design. The current best ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback